Excelimmune garners $4.5M in new financing

Woburn, MA-based Excelimmune has rounded up $4.5 million in new financing for its planned clinical development work on polyclonal antibodies. The financing--roughly half of the $8.9 million the developer is seeking--was detailed in an SEC filing, according to a report in Mass High Tech. Excelimmune picked up $1 million in Series B money near the beginning of the year. Its lead therapy, Staphguard, is being developed for MRSA. So far investigators have completed animal studies and are...